Loading
companiesCompany
zPREDICTA
zPREDICTA grew patient-derived tumour tissue in three-dimensional cultures that reproduce the tumour's surroundings, so drug companies could test cancer drugs on something closer to a real tumour. It was later acquired.
Overview
zPREDICTA developed organ-specific three-dimensional culture models that reconstruct the cellular and extracellular tumour microenvironment, used by pharmaceutical customers for efficacy screening of anti-cancer compounds including immuno-oncology agents, resistance mechanism studies and off-target toxicity assessment. Its YC profile cites clinical study data correlating drug efficacy in the platform with clinical response. The YC directory marks the company as acquired; the acquirer is not recorded here because no primary source was fetched, and the original domain no longer belongs to the company.
Headquarters
San Jose, CA, US
Funding
All startupsAcquiredYC S15
Investors
Type
Stage
Acquired · Y Combinator Summer 2015
Y Combinator profile
Similar pages
- CompanyKnown Medicine
Shares Y Combinator, Functional (ex vivo) drug testing, Patient-derived organoids and the tag yc.
- CompanyOrigin Bio
Shares Y Combinator, Functional (ex vivo) drug testing and the tag yc.
- CompanyNotable Labs
Shares Y Combinator, Functional (ex vivo) drug testing and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.